Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00557765|
Recruitment Status : Completed
First Posted : November 14, 2007
Last Update Posted : November 14, 2007
|Condition or disease|
|Tuberculosis Latent Tuberculosis Infection|
Setting: A TB clinic in Geneva, Switzerland, a low incidence area for TB with a high immigrant population.
Aim of study: to compare results of an IGRA test (T-SPOT.TB, Oxford Immunotec, UK) and the TST, and their correlation with exposure scores in subjects exposed to cases of contagious TB.
Methods: Prospective study of all contacts screened in our area, and accepting to be included. Simultaneous recording of age, gender, origin, history of recent travels or exposure, BCG vaccination status, infectiousness of index case, 5 different exposure scores, TST, and result of the T-SPOT.TB blood test. Univariate and multivariate analysis.
|Study Type :||Observational|
|Actual Enrollment :||295 participants|
|Official Title:||Production of Gamma-Interferon by Circulating Lymphocytes Exposed to Antigens Specific of Mycobacterium Tuberculosis: Contribution to the Identification of Latent Tuberculosis Infection in Contact Tracing|
|Study Start Date :||October 2004|
|Actual Study Completion Date :||January 2006|
- Correlation between results of TST and IGRA tests and exposure scores [ Time Frame: 2 months after exposure ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00557765
|Centre antituberculeux; Geneva University Hospital|
|Geneva, Switzerland, 1211|
|Principal Investigator:||Jean-Paul Janssens, M.D.||Centre antituberculeux|